03.17.26 -- New MIT Consortium Links Innovation With Real-World Biomanufacturing

Harnessing the power of AI, biotherapeutic developers can better understand cellular processes and outcomes This approach is paving the way for more personalized and effective treatments for patients.

Explore how digital systems strengthen CGT manufacturing by improving traceability and managing batch‑of‑one, as well as essential steps toward scalable, integrated operations.

Review the technical workflow for Sf9 cell expansion and protein production. This guide covers virus preparation and GFP expression within stirred-tank environments for optimized bioprocessing.

Discover how lipid nanoparticles are driving breakthroughs in cell therapy, from mRNA-based immune cell engineering to genome editing for CAR T cells and HSPCs from leading experts.

Discover how controlled-rate, directional freezing maintains functional recovery even with lower DMSO concentrations, supporting consistent manufacturing outcomes and enhanced batch reproducibility.

Effective cell concentration and buffer exchange are crucial in MSC biomanufacturing for safety and efficacy. Compare the trade-offs of centrifugation, filtration, and elutriation to optimize your process.

Annex 1’s updated CCS framework calls for a holistic contamination strategy. See how manufacturers can apply it to non-sterile sites and legacy facilities using tailored risk-based approaches.

Gain a targeted look at multiplex digital PCR that detects diverse human viral contaminants with speed, sensitivity, and precision. Learn how high‑multiplex workflows support QC needs.

Use NGS to proactively screen animal-derived reagents in biopharmaceutical production. This method reduces viral contamination risks by identifying potential threats early in the supply chain.

Viral vectors are essential to gene therapy, yet manufacturing remains complex. Examine the biological and technical factors that negatively impact vector stability and yield during production.